

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KANDIL, Osama
Title: Lipid Fraction of Nigella sativa L. Seeds
Appl. No.: 10/809,856
Filing Date: March 26, 2004
Examiner: LEITH, Patricia
Art Unit: 1655
Attorney Docket KAN-002-B

MAIL STOP: AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449 (sheets 1-3). It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

The non-patent literature listed on sheets 1 - 3 of Form PTO-1449 submitted herewith were submitted to the U.S. Patent and Trademark Office in Applicant's prior application Serial

Serial No.: 10/809,856


Attorney Docket No.: KAN-002-B

No. 10/029,885, filed December 31, 2001, now abandoned, which was directed to the same subject matter as the instant application and was examined by the same examiner (Examiner Patricia A. Leith, formerly Patricia A. Patten). Accordingly, Applicant submits that copies of these references are not required under 37 CFR 1.98(d). In addition, in accordance with the revised procedures under 37 CFR 1.98(a)(2)(i), copies of the cited U.S. patent references have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

While Applicant respectfully submits that no fee is required, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 05/05/06By: 

SMITH PATENT CONSULTING, LLC
P.O.Box 2726
Alexandria, VA 22301

Name: Chalin A. Smith
Registration No. 41,569

Tel: 703-549-7691
Fax: 703-549-7692

SHEET 1 OF 3

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. KAN-002-B		SERIAL NO. 10/809,856	
				APPLICANT OSAMA KANDIL			
				FILING DATE March 26, 2004		GROUP 1655	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,231,112		Janoff et al.				
	5,482,711		Mendenica				
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Al-Jassir, M. S. 1992. Chemical composition and microflora of black cumin (<i>Nigella sativa</i> L.) seeds growing in Saudi Arabia. <i>Food Chemistry</i> 45:239-242.						
	Al-Okbi et al. 1997. Studies of some biochemical, nutritional, and anti-inflammatory effects of <i>Nigella sativa</i> seeds. <i>Egypt J. Pharmacy</i> 38 (4-6): 451-469.						
	Atta-ur-rahman, A., Malik, S., Cun-heng, He., and Clardy, J. 1985. Isolation and structure determination of Nigellicine, a novel alkaloid from the seeds of <i>Nigella sativa</i> . <i>Tetrahedron Lett.</i> 26(23):2759-2762.						
	Atta-ur-rahman, A., Malik, S. and Zaman, K. 1992. Nigellimine: A new isoquinoline alkaloid from the seeds of <i>Nigella sativa</i> . <i>J. Nat. Prod.</i> 55(5):676-678.						
	Babayan, V. K., Koottungal, D. and Halaby, G. A. 1978. Proximate analysis, fatty acid and amino acid composition of <i>Nigella sativa</i> L. seeds. <i>J. Food Sc.</i> 43:1314-1315.						
	Badr El-Din, M. K. 1960. The active principle of <i>Nigella sativa</i> L. 'Nigellone' in treatment of asthma in children. <i>Gaz. Egypt. Ped. Assoc.</i> 8(4):864-867.						
	Chakravarty, N. 1993. Inhibition of histamine release from mast cells by nigellone. <i>Ann. Allergy</i> 70:237-242.						
	El-Dakhkhny, M. 1965. Studies on the Egyptian <i>Nigella sativa</i> L. <i>Arzne. Forschung.</i> 15(10):1227-9.						
	El-Naggar, A. M. and El-Deib, A. M. 1992. A study of some biological activity of <i>Nigella sativa</i> (Black Seeds) "Habat El Baraka" <i>J. Egypt. Soc. Pharmacol. Exp. Ther.</i> 11(92):781-797.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 69; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SHEET 2 OF 3

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. KAN-002-B		SERIAL NO. 10/809,856	
				APPLICANT OSAMA KANDIL			
				FILING DATE March 26, 2004		GROUP 1655	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	El Tahir, K. E. H., Ashour, M. M. S. and Al-Harbi, M. M. 1993. The respiratory effects of the volatile oil of the black seed (<i>Nigella Sativa</i>) in guinea pigs: Elucidation of the mechanism(s) of action. <i>Gen. Pharmac.</i> 24(5):1115-1122.						
	Ferdous, A. J., Islam, S. N. <i>et al.</i> 1992. <i>In vitro</i> antibacterial activity of the volatile oil of <i>Nigella sativa</i> seeds against multiple drug-resistant isolates of <i>Shigella</i> spp. and isolates of <i>Vibrio cholerae</i> and <i>Escherichia coli</i> . <i>Phytother. Res.</i> 6:137-140.						
	Hanafy, M. S. M. and Hatem, M. E. 1991. Studies on the antimicrobial activity of <i>Nigella sativa</i> seed (black cumin). <i>J Ethnopharmacol.</i> 34:275-278.						
	Haresh <i>et al.</i> 1989. Effect of certain non-edible seed oils on growth regulation in <i>dysdercus similis</i> . <i>J. Anim. Morphol. Physiol.</i> 36(2): 209-218.						
	Houghton, P. J., Zarka, R. <i>et al.</i> 1995. Fixed oil of <i>Nigella sativa</i> and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. <i>Planta Med.</i> 61:33-36.						
	Isseroff, R.R., Fish again for Dinner! The role of fish and other dietary oils in the therapy of skin disease. 1988 <i>J Am Acad of Derm.</i> 19(6):1073-1080.						
	Mahfouz, M., Abdel-Maguid, R. and El-Dakhakhny, M. 1965. The effect of Nigellone therapy on the histaminopexic power of the blood sera of asthmatic patients. <i>Arzne. Forschung.</i> 15(10):1230-1.						
	Mahfouz, M., Dakakny, M., Gemei, A. and Moussa, H. 1962. Choleric action of <i>Nigella sativa</i> L. seed oil. <i>Egypt. Pharm. Bull.</i> 44(4):225-229						
	Menounos, P., Staphylakis, K. and Gegiou, D. 1986. The sterols of <i>Nigella sativa</i> seed oil. <i>Phytochem.</i> 25(3):761-763.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SHEET 3 OF 3

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. KAN-002-B		SERIAL NO. 10/809,856	
				APPLICANT OSAMA KANDIL			
				FILING DATE March 26, 2004		GROUP 1655	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Nair, S. C., Salomi, M. J., Panikkar, B. and Panikkar, K. R. 1991. Modulatory effects of <i>Crocus sativus</i> and <i>Nigella sativa</i> extracts on cisplatin-induced toxicity in mice. <i>J Ethnopharmacol.</i> 31:75-83.						
	Nergiz C. and Otles, S. 1993. Chemical composition of <i>Nigella sativa</i> L. seeds. <i>Food Chem.</i> 48:259-261.						
	Rao, R. B., Alam, M., Dasan, K. K. S. and Purushothaman, K. K. 1982. Analytical profile of certain ayurvedic drugs used in gastro-intestinal disorders. <i>Nagarjun.</i> June:224-227.						
	Salomi, N. J., Nair, S. C., Jayawardhanan, K. K., Varghese, C. D. and Panikkar, K. R. 1992. Antitumour principles from <i>Nigella sativa</i> seeds. <i>Cancer Lett.</i> 63:41-46.						
	Singh Maurya, D. P., Goyal, S.R., and Sarup, R. 1983. Oestrogenicity of seeds of Kalajaji (<i>Nigella sativa</i>) in female albino rats. <i>Nagarjun</i> May:202-205.						
	Salomi, M. J., Nair, S. C., and Panikkar, K. R. 1991. Inhibitory effects of <i>Nigella sativa</i> and saffron (<i>Crocus sativus</i>) on chemical carcinogenesis in mice. <i>Nutrition and Cancer.</i> 16:67-72.						
	Toppozada, H. H., Mazloun, H. A. and El-Dakhakhny, M. 1960. The antibacterial properties of <i>Nigella Sativa</i> L seeds. Active principle with some clinical applications. <i>J Egypt. Med. Assoc.</i> 48:187-202.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.